1.. Introduction {#s1}
================

Lung cancer, the leading cause of cancer death for both men and women, occurs in the lungs and most often begins in the cells that line the bronchi. Two major types of lung cancer have been identified: small cell lung cancer, which accounts for about 20% of all cases, and non-small cell lung cancer, the most common type. Different types of lung cancers require different kinds of treatments. The age-specific lung cancer incidence rate rises with advancing age and reaches its peak between 65 and 74 \[[@B1]\].

Cancer screening is carried out to detect malignant tumors early, in order to translate into early treatment and a better prognosis. However, there are controversies concerning lung cancer screening since the early 1970s. The benefit of screening is often measured by collecting information on how long patients are alive after the diagnosis, called survival time. The survival time is the time difference between the date the disease is diagnosed and the date a patient dies due to the disease. However, a patient's survival time is often perceived longer due to the earlier date of diagnosis, even though early detection may not be translated into effective treatment in those days. For example, suppose a screening exam leads to a cancer diagnosis at time *t* before any symptoms appear, as shown in [Fig. 1](#F1){ref-type="fig"}, then the survival time will be calculated as (*t~d~* − *t*), although in fact the survival time is (*t~d~* − *t*~2~). This bias occurs due to the contribution of (*t*~2~ − *t*), which is called the lead time. The lead time is the difference between the time of diagnosis via a screening exam and the time of clinical disease onset without screening \[[@B2]\]. Since the survival benefit of screening heavily relies on the lead time, it is critical to accurately evaluate the distribution of the lead time.

![A graphical representation of the disease progressive model.](JEGH-3-3-157-g001){#F1}

For this study, the commonly followed disease progressive model is assumed where the disease develops by progressing through three states, denoted by *S*~0~ → *S~p~* → *S~c~* \[[@B3]\]. Its graphical representation is illustrated in [Fig. 1](#F1){ref-type="fig"}. The state *S*~0~ refers to the disease-free state, where either a person does not have the disease, or the disease is in such an early stage that it cannot be detected by a screening exam. The preclinical disease state, *S~p~*, is a state in which an asymptomatic individual unknowingly has the disease that a screening exam can detect. The disease state, *S~c~*, is a state at which the disease manifests itself with clinical symptoms. If a person enters the preclinical state (*S~p~*) at age *t*~1~ and becomes clinically incident (*S~c~*) later at age *t*~2~(\>*t*~1~), then (*t*~2~ − *t*~1~) is the sojourn time in the preclinical state. However, if this person undergoes a screening exam at time *t* within the time interval (*t*~1~, *t*~2~) and cancer is diagnosed, then the length of time (*t*~2~ − *t*) is the person's lead time.

Many researchers have proposed methods for inference on the lead time among participants in a screening program \[[@B4]--[@B12]\], usually by providing formulas to estimate the mean and the variance of the lead time. Wu et al. \[[@B2]\] derived the probability distribution of the lead time for the whole diseased cohort, including both screen-detected cases and interval-incident cases, where the human lifetime was treated as a fixed value. The model allows estimation of the proportion of patients whose lead time is zero and the proportion whose lead time is positive from the program. Later, Wu et al. applied this approach to the Mayo Lung Project (MLP) data to estimate the lead time distribution \[[@B13]\]. However, it is not realistic to fix a person's lifetime *T* in the estimation of the lead time distribution. For this reason, \[[@B18]\] developed a model to treat the lifetime *T* as a random variable and made the estimation of lead time distribution more practical \[[@B1]\]. The main objective of the present study is to evaluate the lead time distribution in lung cancer screening using the Johns Hopkins Lung Project (JHLP) data and the newly developed method with a changing lifetime *T*.

2.. Materials and methods {#s2}
=========================

The design of the JHLP can be found in the literature \[[@B14]\]. The JHLP trials enrolled 10,386 men in the Baltimore metropolitan area between 1973 and 1978, aged 45 years and older at enrollment, who smoked at least one pack of cigarettes per day (or who had smoked this much within 1 year of enrollment) and who had no prior history of respiratory cancer. Then all participants were randomized into two groups: chest X-ray only, or a dual screen (chest X-ray and sputum cytology) group, resulting in 5160 men in the chest X-ray only group and 5226 in the dual-screen group. Participants in the chest X-ray group received a chest X-ray screening test annually for eight consecutive years. If any of the tests was positive, then the screen was considered positive and a definitive work-up exam, such as biopsy, was done. The data that were used in this study were the chest X-ray group, and the data included the number of participants in each screening exam, the number of detected and confirmed cancer cases in each screening exam, and the number of interval cases. These data were stratified by age at study entry from 45 to 88 years old. However, after carefully examining the data, only the data from age 45 to age 70 were used, excluding age groups 47, 58, 62, 68, 69 and ages above 70, because these age groups had very few participants and might cause a large bias in the estimation.

Consider a cohort of initially asymptomatic individuals in a screening program. Let *β*(*t*) be the sensitivity of the screening modality, where *t* is the individual's age at the exam. Define *w*(*t*)*dt* as the probability of a transition from *S*~0~ to *S*~p~ during (*t*, *t* + *dt*). Let *q*(*x*) be the probability density function (pdf) of the sojourn time in *S~p~*, and let $Q(z) = \int_{z}^{\infty}q(x)\mathit{dx}$ be the survivor function of the sojourn time in the preclinical state *S~p~*. Throughout this paper, the time variable *t* represents the participating individual's age; the random variable *T* represents a person's lifetime with a probability density function *f~T~*(*t*).

For an initially asymptomatic male heavy smoker of age *t*~0~, who has no history of lung cancer, and suppose that he plans to undergo *K* screening exams at ages *t*~0~ \< *t*~1~ \< ... \< *t~K~*~−1~. The distribution of the lead time will be a point mass at 0, and a positive continuous probability density. The reason is that for the screen-detected cases, the lead time is greater than zero, while for the interval incident cases, the lead time is zero. A brief summary of the derived probability formulae for the lead time with a changing human lifetime *T* is given in the [Appendix A](#APP1){ref-type="app"}.

The lead time distribution is a function of the screening sensitivity *β*(*t*), the transition probability density *w*(*t*), the sojourn time distribution *q*(*x*), a person's initial age at screening, and a future screening frequency or screening schedule. The first three parameters were estimated from the JHLP data using the following parametric models: $$\beta(t) = \beta,$$ $$\begin{array}{l}
{w(t|\mu,\sigma^{2}) = {{0.3 \cdot \exp\left\{ {- \frac{{(\text{log}t - \mu)}^{2}}{2\sigma^{2}}} \right\}}/{\left( {\sqrt{2\pi}\sigma t} \right),}}} \\
{\,\,\,\,\,\,\sigma > 0,} \\
\end{array}$$ and $$q(x) = \frac{\kappa x^{\kappa - 1}\rho^{\kappa}}{{(1 + x^{\kappa}\rho^{\kappa})}^{2}},\kappa > 0,\rho > 0,$$ where *t* represents age and *x* is the sojourn time in the preclinical state *S~p~*. The screening sensitivity was treated as a stable value for all age groups, that is, *β*(*t*) = *β*. The lognormal distribution was chosen for *w*(*t*) with an upper limit of 30%. According to the NIH SEER database, the lifetime risk of lung cancer for the general population is about 7% for both genders \[[@B15]\]. Since participants in the JHLP were male heavy smokers, the risk would be higher than that, besides the fact that not all people in the preclinical state will progress into clinical cancer. This research proposes 30% as a reasonable upper limit for *w*(*t*). A more detailed description of the parametric models can be found in Wu et al. \[[@B13],[@B16]\].

In this study, the unknown parameters are *θ* = (*β*, *μ*, *σ*^2^, *κ*, *ρ*). Markov Chain Monte Carlo (MCMC) was used to draw posterior samples with noninformative priors; each simulation was run for 11,000 iterations, with 1000 burn-in steps, and after the burn-in steps, then the posteriors were sampled every 10 steps. The MCMC trace plots and the posterior density plots of *θ* are plotted using the final 1000 posterior samples for *θ*, as can be seen in [Figs. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}. All parameters were converged nicely based on Bayesian output analysis. The posterior means of the parameters are $\widehat{\theta} = (\widehat{\beta},\widehat{\mu},{\widehat{\sigma}}^{2},\widehat{\kappa},\widehat{\rho})$ = (0.568, 3.922, 1.020, 1.027, 1.049). [Table 1](#T1){ref-type="table"} summarizes the estimates of the parameters.

![The MCMC trace plots of the parameters *θ* = (*β*, *μ*, *σ*^2^, *κ*, ρ) using the JHLP data.](JEGH-3-3-157-g002){#F2}

![The posterior density plots of the parameters *θ* = (*β*, *μ*, *σ*^2^, *κ*, *ρ*) using the JHLP data.](JEGH-3-3-157-g003){#F3}

###### 

The estimates of the parameters.

           Mean    SD[^a^](#TFN1){ref-type="table-fn"}   2.5%[^b^](#TFN2){ref-type="table-fn"}   50%[^c^](#TFN2){ref-type="table-fn"}   97.5%[^d^](#TFN2){ref-type="table-fn"}
  -------- ------- ------------------------------------- --------------------------------------- -------------------------------------- ----------------------------------------
  *β*      0.568   0.076                                 0.427                                   0.565                                  0.716
  *μ*      3.922   0.065                                 3.762                                   3.938                                  3.997
  *σ*^2^   1.020   0.022                                 1.001                                   1.014                                  1.079
  *κ*      1.027   0.028                                 1.001                                   1.021                                  1.104
  *ρ*      1.049   0.052                                 1.001                                   1.034                                  1.200

SD stands for the empirical standard deviation.

The 25th, 50th, and 97.5th percentiles, respectively.

3.. Results {#s3}
===========

The Bayesian posterior samples $\theta_{i}^{*}$ in the inference for the lead time were used, where $\theta_{i}^{*}$ is one of the posterior samples generated from the MCMC. The posterior predictive distribution of the lead-time is: $$f_{L}^{\text{JHLP}}(l) \approx \frac{1}{n}\sum\limits_{i = 1}^{n}f_{L}^{\text{JHLP}}(l|\theta_{i}^{*})$$ where $\theta_{i}^{*}$ is the posterior sample (*i* = 1,...,1000) and $f_{L}^{\mathit{HIP}}(l|\theta_{i}^{*})$ is the mixture distribution defined by [Eqs. (A.5)](#FDA5){ref-type="disp-formula"} and [(A.6)](#FDA6){ref-type="disp-formula"}.

For simplicity, three cohorts of initially asymptomatic males were chosen, with initial screening age *t*~0~ = 50, 60, and 70, respectively. For each cohort, various screening frequencies were examined, with screening interval *Δ* = 6, 12, 18, and 24 months. The number of screenings *K* = \[(*T* − *t*~0~)/*Δ*\] is a function of the lifetime *T*, therefore it is a random variable in the simulation. From [Eq. (4)](#FD4){ref-type="disp-formula"}, the final distribution of the lead time is simply a weighted average of the different lengths of lifetimes.

[Table 2](#T2){ref-type="table"} summarizes the Bayesian predictive inference for the lead time. The probability that the lead time is zero and the probability that the lead time is positive are reported as percentages in [Table 2](#T2){ref-type="table"}. The mean lead time and its empirical standard error were reported in years. The density curves for the lead time are shown in [Fig. 4](#F4){ref-type="fig"} for different screening intervals when *t*~0~ = 60, as the density curves when the initial screening age is 50 or 70 are very similar.

![The pdf curve of the lead time when *t*~0~ = 60.](JEGH-3-3-157-g004){#F4}

###### 

A projection of the lead time distribution using the JHLP control group.

  *Δ*[^a^](#TFN3){ref-type="table-fn"}    *P*~0~[^b^](#TFN4){ref-type="table-fn"} (%)   1 − *P*~0~ (%)   Mean (yr)   SE[^c^](#TFN5){ref-type="table-fn"} (yr)
  --------------------------------------- --------------------------------------------- ---------------- ----------- ------------------------------------------
  *Age at initial screen t~0~* *=* *50*                                                                              
  6 mo                                    32.16                                         67.84            1.360       2.278
  12 mo                                   46.30                                         53.70            1.168       2.224
  18 mo                                   54.43                                         45.57            1.038       2.163
  24 mo                                   59.86                                         40.14            0.944       2.106
  *Age at initial screen t~0~* *=* *60*                                                                              
  6 mo                                    32.45                                         67.55            1.332       2.229
  12 mo                                   46.54                                         53.46            1.144       2.175
  18 mo                                   54.58                                         45.42            1.018       2.116
  24 mo                                   59.97                                         40.03            0.926       2.060
  *Age at initial screen t~0~* *=* *70*                                                                              
  6 mo                                    33.17                                         66.83            1.230       2.077
  12 mo                                   47.16                                         52.84            1.051       2.020
  18 mo                                   55.03                                         44.97            0.933       1.960
  24 mo                                   60.22                                         39.78            0.848       1.905

Δ = *t*~*i*~ − *t*~*i*\ −\ 1~ is the time interval between screens.

*P*~0~ = *P*(*L* = 0\|*D* = 1) is the probability of "no-early-detection".

SE stands for the empirical standard error. This is a simulated projection. The number of screens *K* is a random variable, changing with the lifetime *T*.

These results suggest that a man who begins semiannual screening (i.e., *Δ* = 6 months) when he is 60 years old and develops lung cancer sometime during his life has a 32.45% chance that he will not be detected early by the scheduled screening exams. This probability of no-early-detection from the screening program increases to 46.54% if the exams are annual. For a man with initial screening age at 50 \[respectively, 70\], the probability of no-early-detection with semiannual screens will be 32.16% \[or 33.17% for age 70\]. The probability of no-early-detection is monotonically increasing when the screening interval increases within the same age group. This probability is slightly increasing as the initial age increases for the same screening interval. The difference between the initial ages 60 and 70 is smaller than that corresponding difference between the initial age groups 50 and 60.

The mean lead time in each age group decreases as the screening time interval increases in [Table 2](#T2){ref-type="table"} (i.e., more frequent screening exams will result in longer lead times). The increase in the mean lead time is due partly to the smaller point mass at zero of the lead time when screening intervals are closer together. The standard deviation of the lead time decreases as the time between screening exams increases. The mean lead time and the standard error of the lead time both slightly decrease as age increases within the same screening interval. [Table 2](#T2){ref-type="table"} also reveals that the standard deviation for the lead time is greater than the mean lead time.

4.. Discussion {#s4}
==============

The screening sensitivity, the sojourn time distribution, and the transition density were first estimated in a Bayesian framework. The probability distribution of the lead time from the JHLP data was then estimated by employing a newly developed method \[[@B1]\]. This method considers the human lifetime as a random variable using information from the published actuarial life table of the U.S. Social Security Administration to make the screening model more realistic \[[@B17]\].

The sensitivity was considered as a constant parameter across all age groups in this work. Consequently, the estimated sensitivity $\widehat{\beta}$ was 56.8%. Kim et al. (2012) estimated the sensitivity using particle swarm optimization (PSO) using the JHLP study group data, in which both X-ray and sputum cytology were used, when estimating the model parameters. Compared with this previous result, the sensitivity in this study is much smaller than that of the previous result (i.e., 56.8% vs. 79.9%). The reason for the large deviation in sensitivity is that the sensitivity of the previous study was estimated using both X-ray and sputum cytology, while the current study uses the control group data, where only X-ray annual screenings were administered, resulting in a much smaller sensitivity. This confirms that sputum cytology screening improves the overall sensitivity of X-rays.

The density curves of the lead time of the JHLP study group data (i.e., X-ray and cytology screening) were estimated when the lifetime has a fixed upper bound of 75 years old in the previous study \[[@B1]\]. The density curves with the JHLP control group data (i.e., only X-ray) are more skewed to the right than those of the previous study. This in general suggests that the lead time of the JHLP study group data has a greater effect on early detection owing to additional cytology screening, although the lifetime was treated as a random variable for the JHLP control group data.

Some simulation was done for the new lead time model when lifetime *T* is a random variable; the purpose is to find which factor will affect the distribution of the lead time more significantly. Screening sensitivity was found to affect the lead time distribution slightly; it plays a bigger role in the proportion of no-early-detection versus the proportion of early-detection. The sojourn time plays the most significant role in the lead time distribution: in general, a longer (shorter) sojourn time will lead to a longer (shorter) lead time. For lung cancer, the distribution of the sojourn time is heavily skewed to the right, with a large variance; that is why the variance of the lead time in lung cancer is also large.

The lead time model used in this study can answer the following two main questions: the probability that a person's lung cancer will be detected early if a person would develop lung cancer later in life; and the mean/standard error of the lead time for different screening schedules. It is hoped that the results of this study will be beneficial to improving current screening programs.
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This appendix provides a summary of the key formulae in the lead time distribution \[[@B1]\]. For an initially asymptomatic male with no history of lung cancer who plans to take *K* screening exams at ages *t*~0~ \< *t*~1~ \< ... \< *t~K~*~−1~. Let *D* represents the true disease status and *L* represents the lead time. The lead time distribution given that his lifetime *T* = *t~K~*(\>*t~K~*~−1~) is: $$\begin{aligned}
 & {P(L = 0|D = 1,T = t_{K}) = P(L = 0,D = 1|T = t_{K})/P(D = 1|T = t_{K})} \\
 & \text{and} \\
 & {f_{L}(z|D = 1,T = t_{K}) = f_{L}(z,D = 1|T = t_{K})/P(D = 1|T = t_{K}),} \\
\end{aligned}$$ where $$\begin{array}{l}
\left. P(D = 1 \middle| T = t_{K}) \right. \\
{\,\,\,\,\,\,\,\,\,\, = \int\limits_{0}^{t_{0}}w(x)\lbrack Q(t_{0} - x) - Q(t_{K} - x)\rbrack dx} \\
{\,\,\,\,\,\,\,\,\,\,\,\,\,\,\, + {\int_{t_{0}}^{t_{K}}{w(x)\lbrack 1 - Q(t_{K} - x)\rbrack dx,}}} \\
\end{array}$$ $$\begin{aligned}
 & {P(L = 0,D = 1|T = t_{K}) = I_{K,1} + I_{K,2} + \cdots + I_{K,K},} \\
 & {I_{K,j} = \sum\limits_{i = 0}^{j - 1}(1 - \beta_{i})\cdots(1 - \beta_{j - 1})\int_{t_{i - 1}}^{t_{i}}w(x)\lbrack Q(t_{j - 1} - x) - Q(t_{j} - x)\rbrack\mathit{dx}} \\
 & {+ \int_{t_{j - 1}}^{t_{j}}w(x)\lbrack 1 - Q(t_{j} - x)\rbrack\mathit{dx},\text{for}\,\text{all}j = 1,\ldots,K,} \\
\end{aligned}$$ and $$\begin{array}{l}
{f_{L}\left( z,D = 1 \middle| T = t_{K} \right) = \sum\limits_{i = 1}^{j - 1}\beta_{i}\left\{ {\sum\limits_{r = 0}^{i - 1}{\left( {1 - \beta_{r}} \right)\ldots\left( {1 - \beta_{i - 1}} \right)}} \right.} \\
{\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\, \times {\int_{t_{r - 1}}^{t_{r}}{w\left( x \right)q\left( {t_{i} + z - x} \right)dx}} + {\int_{t_{i - 1}}^{t_{i}}{w\left( x \right)q}}(t_{i}} \\
{\left. \,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\, + z - x)dx \right\} I\left( {j > 1} \right) + \beta_{0}{\int_{0}^{t_{0}}{w\left( x \right)q\left( {t_{0} + z - x} \right)}}dx,} \\
{\,\,\,\,\,\,\,\,\,\,\,\,\,\,\, t_{K} - t_{j} < z \leq t_{K} - t_{j - 1},j = 2,3,\ldots,K.} \\
\end{array}$$ For an individual currently at age *t*~0~, his lifetime is a random variable, hence the number of screenings is random as well. However, if he plans to follow a pre-planned screening schedule, then the distribution of lead time when the lifetime *T* is greater than *t*~0~ can be obtained by: $$\begin{array}{l}
{P\left( L = 0 \middle| D = 1,T \geq t_{0} \right) = {\int_{t_{0}}^{\infty}\left. P(L = 0 \middle| D = 1,T \right.}} \\
{\,\,\,\,\,\,\,\,\,\,\, = t)f_{T}\left( t \middle| T \geq t_{0} \right)dt,} \\
{f_{L}\left( z \middle| D = 1,T \geq t_{0} \right) = {\int_{t_{0} + z}^{\infty}\left. f_{L}\left( z \middle| D = 1,T = t \right)f_{T}(t \middle| T \right.}} \\
{\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\, \geq t_{0})dt,\,\,\,\,\,\,\,\,\,\, z \in (0,\infty),} \\
\end{array}$$ where the conditional pdf of the lifetime is $$\begin{array}{l}
{f_{T}(t|T \geqslant t_{0})} \\
{\,\,\,\, = f_{T}(t)/P(T > t_{0}) = f_{T}(t)/\lbrack 1 - F_{T}(t_{0})\rbrack,\mathit{if}t \geqslant t_{0}.} \\
\end{array}$$ This is a valid mixed probability distribution, because it was proved that $$P(L = 0|D = 1,T \geqslant t_{0}) + \int_{0}^{\infty}f_{L}(z|D = 1,T \geqslant t_{0})\mathit{dz} = 1.$$ To obtain reliable information on the lifetime distribution, the actuarial life table from the United States Social Security Administration (SSA) was used \[[@B17]\]. For more detailed overviews of the methods for lead time calculation and for the lifetime prediction, refer to Wu et al. (2012).

[^1]: Tel.: +1 502 852 8078.

[^2]: Tel.: +1 502 852 3525.
